News
ESC: MSD/Bayer's Verquvo disappoints in heart failure trial
Bayer and MSD's hopes of expanding the use of Verquvo in heart failure have been dashed by a failed phase 3 trial.
Market Access
Sponsored
Bridging research and clinical guidelines – interactive stra...
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Market Access
12 questions with: Daniel Kohlstaedt
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
R&D
Life Sciences Industry Report - Biologics and Generics
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
R&D
Increasing trial efficiency: Adityo Prakash talks small data...
Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
Oncology
Life Sciences Industry Report - Oncology
Developments in the oncology space in 2024 brought hope to both industry and patients.
Partner Content
Partner Content
The Antifibrotic Drug Development Summit returns this Novemb...
Harness cross-fibrotic insights and make new connections this November in Boston
R&D
Partner Content
Revolutionising Clinical Trials: Evolution Summit 2025 Retur...
Marcus Evans is proud to announce the Evolution Summit September 2025, an exclusive, invitation-only event bringing together leading clinical trial executives, innovative suppliers
